Edwards Lifesciences Corp. lost more than a fifth of its market value as it turned in the biggest decline on the S&P 500. The company, which makes a less-invasive heart valve, generated an estimated $448 million in sales during the latest quarter, less than the $465 million to $485 million that was estimated in July, the company said.